FDA approves Vaxelis six-in-one vaccine.- Sanofi Pasteur + MSD.
The FDA has approved Vaxelis (diphtheria, tetanus, pertussis, poliovirus, haemophilus b and hepatitis B vaccine) for use in children from 6 weeks through 4 years of age (prior to the 5th birthday), from Sanofi Pasteur and MSD. Sanofi and MSD are working to maximize production of Vaxelis to allow for a sustainable supply to meet anticipated US demand. Commercial supply will not be available in the US prior to 2020.
Comment: The new vaccine has already been commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins